ChemoCentryx to Hold Third Quarter 2020 Financial Results Conference Call on Monday, November 9, 2020

Rhea-AI Summary

ChemoCentryx (NASDAQ: CCXI) will release its third quarter 2020 financial results on November 9, 2020, after market close. A conference call and webcast for investors will follow at 5:00 p.m. ET the same day. The company focuses on developing drugs for autoimmune and inflammatory diseases, with its lead candidate, avacopan (CCX168), under FDA review after a successful Phase III trial for ANCA-associated vasculitis. Avacopan is also being tested for Hidradenitis Suppurativa and C3 glomerulopathy.

Positive

• Avacopan (CCX168) completed a pivotal Phase III trial successfully.
• New Drug Application for avacopan is under review by the FDA.
• Avacopan is in late-stage development for multiple indications.

Negative

• None.

MOUNTAIN VIEW, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2020 financial results will be released after market close on Monday, November 9, 2020. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on November 9, 2020 to discuss these results and to answer questions.

To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (International). The conference ID number is 7147318. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.

About ChemoCentryx
ChemoCentryx is a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of Hidradenitis Suppurativa and C3 glomerulopathy (C3G).

ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Contacts:

Susan M. Kanaya                                        
Executive Vice President,                                         
Chief Financial and Administrative Officer
investor@chemocentryx.com                                

Media:
Stephanie Tomei
408.234.1279
media@chemocentryx.com

Investors:
Steve Klass, Burns McClellan
212.213.0006
sklass@burnsmc.com

FAQ

When will ChemoCentryx release its third quarter 2020 financial results?

ChemoCentryx will release its third quarter 2020 financial results on November 9, 2020, after market close.

What is the conference call time for ChemoCentryx's third quarter results?

The conference call will begin at 5:00 p.m. Eastern Time on November 9, 2020.

What are the key focuses of ChemoCentryx's drug development?

ChemoCentryx focuses on developing medications for inflammatory and autoimmune diseases, as well as cancer.

What is the status of avacopan (CCX168)?

Avacopan has successfully completed a Phase III trial for ANCA-associated vasculitis and is under FDA review.

Which other conditions are being targeted by avacopan?

Avacopan is also in late-stage clinical development for Hidradenitis Suppurativa and C3 glomerulopathy.